Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., has announced results from a recent online survey of 200 radiology professionals, uncovering perspectives and expectations, with a focus on MRI contrast agents. Photo credit: Getty Images
December 5, 2022 — Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., has announced results from a recent online survey of 200 radiologists. In issuing its findings, the company reports that over half (53%) of radiology professionals responding saw an increase in MRI procedures over the last year, and another one in two (55%) have concerns about the availability of gadolinium-based contrast agents (GBCAs) for use in magnetic resonance imaging (MRI) procedures.
The shortage of iodinated contrast for computed tomography scans in early 2022 may be one aspect fueling concerns over supply chain disruptions, according to a summary of findings. Radiologists in small hospitals express the highest level of concern (75%) about the availability of gadolinium-based contrast agents compared to 35% from radiologists at larger institutions. The survey also finds that 63% of radiologists believe it is important for contrast agents to be manufactured in the U.S, with 88% explaining products manufactured in the U.S. – through closed supply chains – are one option to lessen concerns about availability.
When asked to rank factors critical to the success of their radiology practices, professionals listed supply availability (87%), image quality (92%), and patient safety (93%) above other options such as revenue generation, staff training, and sustainable practices.
The findings further noted that an astonishing 99% of radiologists confirm they are interested in using an MRI contrast agent that contains half the amount of gadolinium, with the breakdown being 60% very interested and 39% somewhat interested, according to the survey summary of findings issued by Bracco, a global diagnostic imaging provider, based in Milan, Italy.
Bracco’s statement also reported radiologists are confident about keeping pace with advancements in the field but acknowledge challenges and opportunities. Harnessing Artificial Intelligence (AI), healthcare spending, and attracting future talent are the foremost challenges.
The national quantitative survey commissioned by Bracco, in collaboration with global medical research company Sermo, delved into the perspectives and expectations of 200 radiology professionals, with a specific focus on MRI contrast agents. The survey captured quantitative data from 20 Technologists/Technicians, 164 MRI Radiologists/Chief Radiologists, and 16 Imaging Directors, with the majority of respondents working in a hospital (147), with imaging centers (40) and (13) representing outpatient departments, and was conducted between Oct. 26-Nov. 4, 2022.
“These survey results inspire us to continue advancing innovation in 2023 and beyond,” said Fulvio Renoldi Bracco, Vice-Chairman & CEO of Bracco Imaging. Bracco added, “A key takeaway for the diagnostic imaging industry at large is that the road to innovation often lacks involvement from radiologists themselves. By bringing in the perspectives of those on the frontlines, through surveys such as this and other means, Bracco continues to hone our focus for where to improve techniques and processes in ways that will maximize clinical benefits.”
Other key survey insights:
- More than a quarter (26%) of radiologists experienced issues with the availability of gadolinium-based contrast agents in the past few years.
- While there is some concern (46%) about the use of gadolinium-based contrast agents, there is greater concern about the amount of gadolinium-based contrast agents (86%).
- Just over a third of radiologists (35%) say their patients express concerns about MRI contrast agents used in their bodies – no surprise considering 41% of radiologists say their patients are more informed about MRI contrast agents than just a few years ago.
- More than a third of radiologists (35%) are thinking about environmental impact, and sustainability more than they did a few years ago.
“We are continually listening to and value the needs of radiologists,” said Cosimo De Pinto, Senior Vice President of Sales and Marketing at Bracco Diagnostics Inc. “The results of this survey mirror what we have been hearing from our customers: Health care professionals (HCPs) are concerned about the availability and supply of contrast media, a key part of the diagnostic process. That is one of the key reasons we made a strategic, global collaboration with Guerbet in both research, development, and manufacturing of VUEWAY injection. This strategic collaboration will expand access to this important new contrast agent which has the potential to help improve diagnoses and ultimately improve patient care," he added.
For more information: www.bracco.com
Related Content:
RSNA 2022: Innovative Solutions on Display, Leadership Addresses Value of Imaging
Bracco and Guerbet Partner to Expand Access to Novel Imaging Agent
Guerbet Announces FDA Approval of Elucirem (Gadopiclenol) for Use in Contrast-enhanced MRI
April 25, 2024 
